Inoculation of dysentery Sonne

Dysentery Sonne is the most common form of dysentery in Russia; in 2006, 36092 cases were affected by shigellosis, in 2007 - 31632 people (incidence, respectively, 25.1 and 22.1 per 100 000), with children under 17 accounting for more than half of the cases (with a incidence of 69.1 and 62, respectively , 15 per 100 000).

[1], [2], [3], [4], [5], [6], [7]

Goals of immunization against dysentery Sonne

Vaccination from dysentery Sonne is administered to children from 3 years of age and adults. Priority vaccination against dysentery Sonne is recommended for:

• employees of infectious hospitals and bacteriological laboratories;
• persons engaged in public catering and public amenities;
• children attending children's institutions and going to health camps;
• Persons departing to regions with a high incidence of dysentery Sonne.

According to epidemiological evidence, mass immunization of the population is carried out with the threat of an epidemic or an outbreak (natural disasters, etc.). Vaccination from dysentery Sonne is carried out before the seasonal rise in morbidity. In Russia, the vaccine Shigellvak - purified lipopolysaccharide from the culture of S. Sonei was registered. Preservative is phenol. The introduction of the vaccine after 2-3 weeks provides immunity to infection within 1 year. The coefficient of drug effectiveness is 92.4%. It is produced in ampoules of 1 ml in a package of 5 or 10 ampoules.

Inoculation from dysentery Sonne: Doses and method of administration

Shigellvak vaccine is injected once, deeply subcutaneously or intramuscularly into the outer surface of the upper third of the shoulder. The dose for all ages is 0.5 ml (50 μg). Revaccination against dysentery is carried out, if necessary, once a year, with the same dose.

Adverse Events

Reactions are rare and weak: in the first day, redness and soreness at the injection site, temperatures up to 37.6 ° (3-5% - for 24-48 hours), sometimes headache.

[8], [9], [10], [11], [12], [13], [14], [15],